Our Portfolio

Rhododendron Biotech Pvt. Ltd

DIF I Investment

USD 1.8 Million

Investment Date

October 2016


Direct Jobs


Youth Employment


Female Employment


Districts Covered


Hospitals (Direct/Indirect Supplies)

438,888 Units

Hemodialysis Fluid Distributed


Job Growth Since Investment

Established in 2009, Rhododendron Biotech Pvt. Ltd (RBPL) specialises in pharmaceutical manufacturing, notably the production of haemodialysis fluid, a critical product for kidney patients in Nepal. Despite initial success, RBPL faced sluggish growth in 2014-2015. In 2016, Dolma Impact Fund I became an equity partner, providing much-needed capital and unlocking growth potential. The immediate impact was a remarkable 109% revenue growth in 2016.

In 2021, DOS Group joined forces with Dolma, bringing strategic investors with extensive Nepal business experience. Dolma facilitated a technical assistance program, enabling RBPL to hire finance and business consultants, streamline operations, and prepare for a new facility. RBPL now supplies 95% of dialysis centres in Nepal.

The company’s success continued, with a 37% revenue increase in 2022, resulting in a 314% profit rise. Significant renovations were made to the factory, including automation, expanded R&D, and a focus on quality improvement and cost reduction. RBPL plans to venture into powdered drugs and tablets/capsules, constructing a new facility and conducting R&D. They recently launched two disinfecting agents: CITROL-M PLUSTM and RB-CHLORITE TM.

To Learn More About Rhododendron Biotech Pvt. Ltd